top of page

Free Biopharma Daily Stock Updates - 01/13/22

$XBI $98.10 -2.5%

 

Covid Updates

$RDHL -1.6% RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients source


$GSK -0.4% GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19 source


Pipeline Updates

$RYTM +0.6% Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity source


$JAGX -6.9% Jaguar Health Provides Corporate Update and Outlines 2022 Milestones source


$RMTI +17.4% Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea source


$ASND -2.3% Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency source


$DNLI -12.2% Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application source


$RUBY -5.9% Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors source


$ACHL -6.0% Achilles Therapeutics Provides Business Update and Outlook for 2022 source


$ENDP -6.2% Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism source


$GRTS -4.0% Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC) source


$ADAG -1.6% Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore source



Business Updates

$BBIO -4.5% bridgebio announces clinical collaboration with amgen to study bbp-398, a potentially best-in-class shp2 inhibitor, in combination with lumakras® (sotorasib) in advanced solid tumors with the kras g12c mutation source


$DERM -3.9% Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc. source


$AZN -0.5% AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets source


 

Posted by JM

0 comments
bottom of page